Trial supported Orphalan’s successful application to the United States Food and Drug Administration (FDA) for approval of Cuvrior™ (trientine tetrahydrochloride) for Wilson’s disease Paris, France 30 September, 2022 - Orphalan…
World’s first global Wilson’s Registry will provide an international platform for sharing real-world information about Wilson’s disease Registry expected to include 500 individuals affected by this rare disease Paris, France…
Paris, France 1 February 2022 – Orphalan SA, a Company that identifies, develops, and delivers therapies worldwide for orphan diseases, today announces two new appointments to the management team. Tim…
At Orphalan we identify, develop and provide access to innovative treatments for patients with rare diseases. The information available on this Website is for information purposes only.
We work in a highly-regulated industry with unique legal considerations. Medical and health information may be presented but the content we share is not intended to provide professional medical advice, diagnosis or treatment.
Always seek medical advice from qualified health care professional for any questions you may have regarding your medical condition.
To report an adverse event experience for any Orphalan product please contact us by writing to AdverseEventReporting@orphalan.com or calling direct: +356 2776 1718, or calling the local toll free telephone number listed under your country and choosing option 3.
226 Boulevard Voltaire
Tel : +33 (0)1 42 49 82 64